IMMUNIC INC (IMUX)

US4525EP1011 - Common Stock

1.32  +0.02 (+1.54%)

Fundamental Rating

2

We assign a fundamental rating of 2 out of 10 to IMUX. IMUX was compared to 592 industry peers in the Biotechnology industry. The financial health of IMUX is average, but there are quite some concerns on its profitability. IMUX has a expensive valuation and it also scores bad on growth.



0

1. Profitability

1.1 Basic Checks

In the past year IMUX has reported negative net income.
IMUX had a negative operating cash flow in the past year.
In the past 5 years IMUX always reported negative net income.
IMUX had a negative operating cash flow in each of the past 5 years.

1.2 Ratios

Looking at the Return On Assets, with a value of -172.40%, IMUX is doing worse than 88.78% of the companies in the same industry.
IMUX's Return On Equity of -323.57% is on the low side compared to the rest of the industry. IMUX is outperformed by 77.04% of its industry peers.
Industry RankSector Rank
ROA -172.4%
ROE -323.57%
ROIC N/A
ROA(3y)-111.15%
ROA(5y)-82.52%
ROE(3y)-167.53%
ROE(5y)-118.03%
ROIC(3y)N/A
ROIC(5y)N/A

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for IMUX so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A

5

2. Health

2.1 Basic Checks

Compared to 1 year ago, IMUX has more shares outstanding
The number of shares outstanding for IMUX has been increased compared to 5 years ago.
There is no outstanding debt for IMUX. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.

2.2 Solvency

IMUX has an Altman-Z score of -13.24. This is a bad value and indicates that IMUX is not financially healthy and even has some risk of bankruptcy.
IMUX has a Altman-Z score of -13.24. This is amonst the worse of the industry: IMUX underperforms 83.33% of its industry peers.
IMUX has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -13.24
ROIC/WACCN/A
WACCN/A

2.3 Liquidity

A Current Ratio of 2.12 indicates that IMUX has no problem at all paying its short term obligations.
The Current ratio of IMUX (2.12) is worse than 77.55% of its industry peers.
A Quick Ratio of 2.12 indicates that IMUX has no problem at all paying its short term obligations.
IMUX has a worse Quick ratio (2.12) than 76.02% of its industry peers.
Industry RankSector Rank
Current Ratio 2.12
Quick Ratio 2.12

1

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 44.03% over the past year.
EPS 1Y (TTM)44.03%
EPS 3YN/A
EPS 5YN/A
EPS growth Q2Q70.37%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Revenue growth Q2QN/A

3.2 Future

Based on estimates for the next years, IMUX will show a very strong growth in Earnings Per Share. The EPS will grow by 39.95% on average per year.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y51.62%
EPS Next 2Y24.66%
EPS Next 3Y36.21%
EPS Next 5Y39.95%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

1

4. Valuation

4.1 Price/Earnings Ratio

IMUX reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year IMUX is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A

4.3 Compensation for Growth

IMUX's earnings are expected to grow with 36.21% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y24.66%
EPS Next 3Y36.21%

0

5. Dividend

5.1 Amount

IMUX does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

IMMUNIC INC

NASDAQ:IMUX (3/28/2024, 9:30:01 AM)

1.32

+0.02 (+1.54%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap118.71M
Analysts
Price Target
Dividend
Industry RankSector Rank
Dividend Yield N/A
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S
P/FCF
P/OCF
P/B
P/tB
EV/EBITDA
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -172.4%
ROE -323.57%
ROCE
ROIC
ROICexc
ROICexgc
OM N/A
PM (TTM) N/A
GM N/A
FCFM
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF
Debt/EBITDA
Cap/Depr
Cap/Sales
Interest Coverage
Cash Conversion
Profit Quality
Current Ratio 2.12
Quick Ratio 2.12
Altman-Z
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
Growth
EPS 1Y (TTM)44.03%
EPS 3YN/A
EPS 5Y
EPS growth Q2Q
EPS Next Y51.62%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5Y
Revenue growth Q2Q
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y